Morgan Stanley lowered the firm’s price target on Johnson & Johnson to $163 from $175 and keeps an Equal Weight rating on the shares following what the firm views as “generally in line” 2025 guidance. After the Q4 report, the firm made a number of adjustments to its model, noting that J&J expects a more pronounced impact from new product cycles as the year progresses and pointed to Rybrevant plus Lazcluze in NSCLC and Tremfya in IBD as two key drivers.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on JNJ:
- Johnson & Johnson price target lowered to $158 from $160 at Bernstein
- Johnson & Johnson publishes nipocalimab study results in The Lancet Neurology
- Johnson & Johnson price target lowered to $152 from $166 at Wells Fargo
- Johnson & Johnson Reports Strong 2024 Financial Results
- Johnson & Johnson Earnings Report: Is it a Beat?
Questions or Comments about the article? Write to editor@tipranks.com